Telix Pharmaceuticals Limited American Depositary Shares (TLX)

• Market cap: $5.3B
• 1 day: -3.18%
• 5 days: -5.16%
• 1 month: 5.47%
• 3 months: 6.53%
• 6 months: 6.53%
• Year to date: 6.53%
• 1 year: 6.53%
• 5 years: 6.53%
• 10 years: 6.53%

About: Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Employees: 234

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $21 33% upside
• Avg. target: $21 33% upside
• High target: $21 33% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

UBS Laura Sutcliffe 100% 1-year accuracy 1 / 1 met price target

33% upside $21

Buy Initiated

15 Nov 2024